Baylor College of Medicine Cancer Center

贝勒医学院癌症中心

• 批准号: 7933201
• 负责人: C KENT OSBORNE
• 金额: $ 5万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2012-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7933201
• 关键词: Baylor; College; Medicine; Cancer; Center

DESCRIPTION (provided by applicant): This is the initial application of the Baylor College of Medicine Cancer Center (BCMCC) for NCI designation and is being submitted in the 3rd year of an NCI P20 planning grant. Baylor College of Medicine (BCM) is located in the Texas Medical Center (TMC) in Houston, the largest and perhaps most complex medical center in the country with 40 member institutions. Houston is the 4th largest city in the US with a very diverse population. The BCMCC is a consortium cancer center with BCM as the lead partner, and our four hospital affiliates, Texas Children's Hospital, St. Luke's Episcopal Hospital, The DeBakey Veterans Affairs Medical Center, and Ben Taub General Hospital, as formal clinical partners. In addition, as part of a BCM strategy to create its own ambulatory care facilities, the BCMCC is leading the planning for a comprehensive multidisciplinary cancer clinic to be completed in 2008. The BCMCC was formally established in 2002 to integrate the already strong and organized scientific and clinical programs at BCM and our partners, and to create new synergies and programs that take advantage of this unique environment. The unique environment of the TMC creates many opportunities for scientific, clinical, and educational collaborations, of which the BCMCC takes full advantage. The BCMCC has been given the resources and authority to be successful at this task and has made exciting progress over the past three years. It now includes over 260 formal members, and total annual cancer-relevant research funding documented in this proposal approaches $100 million, with close to $40 million coming from the NCI. The 8 research and translational Programs that were organized through the P-20 process remain in place and are growing stronger. These Programs are Cancer Biology, Molecular Carcinogenesis, Nuclear Receptors, Breast Cancer, Cancer Cell and Gene Therapy, Prostate Cancer, Cancer Prevention, and Pediatric Cancer. In addition, although relatively new, the Center has already fostered interactions among its members that have led to several developing research programs including pancreas cancer, genomic instability, and stem cell biology among others. In addition 9 Shared Research Resources are included in this application; 6 based on strong-capabilities present at BCM, and 3 (Biostatistics, the Clinical Trials Support Unit, and Pathology and Tissue Banking), created through BCMCC leadership and/or funding. The Center has also established an Office of Outreach and Health Disparities to better translate our extensive research expertise in this area into more coordinated community action among our partners and colleagues in the TMC and the region. Finally, the BCMCC has been recently blessed with a $100 million philanthropic gift from a wonderful Houston family. This gift has been entirely dedicated to support the development of the Center, its programs and its members and to foster collaboration with other institutions. Substantial funds will be available for use in the next year even as a long term endowment is created to ensure future stability. Thus, the CCSG outlines an organizational structure, outstanding leadership, integrated scientific research programs, expert Shared Resources, a process for community outreach, adequate and diverse patient resources, and the institutional support to build an outstanding NCI-designated Cancer Center that will benefit the Houston Community and region.

描述（由申请人提供）：这是贝勒医学院癌症中心 (BCMCC) 首次申请 NCI 指定，并在 NCI P20 规划拨款的第三年提交。贝勒医学院 (BCM) 位于休斯敦的德克萨斯医学中心 (TMC)，该中心是美国最大、或许也是最复杂的医疗中心，拥有 40 个成员机构。休斯顿是美国第四大城市，人口非常多元化。 BCMCC 是一个癌症中心联盟，以 BCM 为主要合作伙伴，我们的四家附属医院（德克萨斯儿童医院、圣卢克圣公会医院、德贝基退伍军人事务医疗中心和本陶布综合医院）为正式临床合作伙伴。此外，作为 BCM 创建自己的门诊护理设施战略的一部分，BCMCC 正在牵头规划将于 2008 年完成的综合性多学科癌症诊所。BCMCC 于 2002 年正式成立，旨在整合 BCM 和我们的合作伙伴已经强大且有组织的科学和临床项目，并利用这一独特的环境创造新的协同效应和项目。 TMC 独特的环境为科学、临床和教育合作创造了许多机会，BCMCC 充分利用了这些机会。 BCMCC 已获得成功完成这项任务的资源和权力，并在过去三年中取得了令人兴奋的进展。它现在包括 260 多名正式成员，该提案中记录的年度癌症相关研究经费总额接近 1 亿美元，其中近 4000 万美元来自 NCI。通过 P-20 进程组织的 8 个研究和转化计划仍然存在，并且正在变得更加强大。这些项目包括癌症生物学、分子癌变、核受体、乳腺癌、癌细胞和基因治疗、前列腺癌、癌症预防和小儿癌症。此外，尽管相对较新， 该中心已经促进了其成员之间的互动，从而促成了多个正在开发的研究项目，包括胰腺癌、基因组不稳定性和干细胞生物学等。此外，该应用程序还包含 9 个共享研究资源； 6 个基于 BCM 现有的强大能力，3 个（生物统计学、临床试验支持单位以及病理学和组织库）是通过 BCMCC 的领导和/或资助创建的。该中心还设立了外展和健康差异办公室，以更好地将我们在该领域的广泛研究专业知识转化为 TMC 和该地区的合作伙伴和同事之间更加协调的社区行动。最后，BCMCC 最近获得了来自休斯敦一个优秀家庭的 1 亿美元慈善捐赠。这笔捐款完全致力于支持该中心、其项目及其成员的发展，并促进与其他机构的合作。即使创建长期捐赠以确保未来稳定，明年也将有大量资金可供使用。因此，CCSG 概述了组织结构、杰出的领导力、综合科学研究计划、专家共享资源、社区外展流程、充足且多样化的患者资源以及机构支持，以建立一个优秀的 NCI 指定的中心 癌症中心将使休斯顿社区和地区受益。